Mahy P, De Bast M, Gillart J, Labar D, Grégoire V
Center for Molecular Imaging and Experimental Radiotherapy, Université Catholique de Louvain and St-Luc University Hospital, 10 Ave Hippocrate, 1200, Brussels, Belgium.
Eur J Nucl Med Mol Imaging. 2006 May;33(5):553-6. doi: 10.1007/s00259-005-0049-3. Epub 2006 Mar 8.
In the framework of the preclinical validation of the hypoxic tracer [(18)F]EF3, a comparison was performed between uptake of [(18)F]EF3 and EF5 adducts detected by immunofluorescence in MCa-4, FSA, FSAII, Sa-NH and NFSA tumour-bearing mice. Mice were allowed to breath carbogen (5% CO(2), 95% O(2)), 21% oxygen or 10% oxygen. A significant correlation (r (2)=0.57; p<0.01) was found between the [(18)F]EF3 tumour-to-muscle ratio and the fluorescence intensity of EF5.
在缺氧示踪剂[(18)F]EF3的临床前验证框架内,对MCa-4、FSA、FSAII、Sa-NH和NFSA荷瘤小鼠中通过免疫荧光检测到的[(18)F]EF3摄取与EF5加合物进行了比较。让小鼠呼吸混合气(5%二氧化碳,95%氧气)、21%氧气或10%氧气。发现[(18)F]EF3肿瘤与肌肉的比值与EF5的荧光强度之间存在显著相关性(r(2)=0.57;p<0.01)。